Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nurix Therapeutics Inc shares valued at $69,273 were sold by Ring Christine on Jan 20 ’26. At $18.42 per share, Ring Christine sold 3,760 shares. The insider’s holdings dropped to 50,897 shares worth approximately $0.97 million following the completion of this transaction.
Also, Ring Christine sold 3,760 shares, netting a total of over 67,314 in proceeds. Following the sale of shares at $17.90 each, the insider now holds 50,897 shares.
Before that, CHRISTINE RING had added 7,520 shares to its account. In a trade valued at $136,939, the Officer bought Nurix Therapeutics Inc shares for $18.21 each.
As published in a research note from Morgan Stanley on January 08, 2026, Nurix Therapeutics Inc [NRIX] has been rated up from an Equal-weight to an Overweight and the price target has been revised to $36. As of October 21, 2025, Mizuho has initiated its “an Outperform” rating for NRIX. Earlier on March 17, 2025, Leerink Partners initiated its rating. Their recommendation was “a Market perform” for NRIX stock.
Analyzing NRIX Stock Performance
On last trading session, Nurix Therapeutics Inc [NASDAQ: NRIX] rose 4.28% to $19.02. The stock’s lowest price that day was $18.15, but it reached a high of $19.15 in the same session. During the last five days, there has been a surge of approximately 0.48%. Over the course of the year, Nurix Therapeutics Inc shares have dropped approximately -0.63%.
Is Nurix Therapeutics Inc subject to short interest?
Stocks of Nurix Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.16 million shares to 14.64 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 14.49 million shares. A jump of 1.07% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.68 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.68.
Which companies own the most shares of Nurix Therapeutics Inc (NRIX)?
In terms of Nurix Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 64.47% from the previous closing price of $18.24. Analysts anticipate Nurix Therapeutics Inc stock to reach 36 by 2026, with the lowest price target being 21. In spite of this, 16 analysts ranked Nurix Therapeutics Inc stock as Buy at the end of 2026. On December 10, 2024, BTIG Research assigned a price target of “a Buy” to the stock and initiated coverage with a $35.
